Farther Finance Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.23M Buy
28,699
+6,427
+29% +$349K 0.01% 977
2026
Q1
$1.38M Buy
22,272
+1,881
+9% +$150K 0.01% 812
2025
Q4
$1.94M Buy
20,391
+2,409
+13% +$236K 0.02% 592
2025
Q3
$1.76M Buy
17,982
+4,903
+37% +$508K 0.03% 500
2025
Q2
$1.4M Buy
13,079
+1,017
+8% +$103K 0.03% 475
2025
Q1
$1.22M Buy
12,062
+1,002
+9% +$101K 0.03% 435
2024
Q4
$988K Sell
11,060
-263
-2% -$23.2K 0.04% 374
2024
Q3
$949K Buy
11,323
+580
+5% +$45.7K 0.04% 361
2024
Q2
$821K Buy
10,743
+6,597
+159% +$483K 0.04% 342
2024
Q1
$282K Buy
4,146
+351
+9% +$22.6K 0.02% 575
2023
Q4
$219K Buy
3,795
+2,217
+140% +$118K 0.02% 527
2023
Q3
$83.3K Buy
1,578
+306
+24% +$16K 0.01% 624
2023
Q2
$68.8K Buy
1,272
+108
+9% +$5.64K 0.02% 572
2023
Q1
$58.2K Sell
1,164
-27
-2% -$1.27K 0.02% 566
2022
Q4
$55.1K Buy
+1,191
New +$51.6K 0.02% 464

Other funds holding BSX

Farther Finance Advisors's BSX Position: Q2 2026 in Review

Farther Finance Advisors increased its Boston Scientific (BSX) stake by 29% in Q2 2026, buying an estimated $349K and bringing the position to 28,699 shares worth $1.23M. The position accounts for 0.01% of the portfolio, ranked #977.

Farther Finance Advisors first reported a position in BSX in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.94M in Q4 2025. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Farther Finance Advisors held 28,699 shares of Boston Scientific worth $1.23M as of Q2 2026.
  • Farther Finance Advisors bought 6,427 Boston Scientific shares in Q2 2026, an estimated $349K.
  • Boston Scientific made up 0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #977 holding.
  • Farther Finance Advisors first reported a position in Boston Scientific in Q4 2022 and has held it in 15 quarters since.
  • Farther Finance Advisors's Boston Scientific position peaked at $1.94M in Q4 2025.
  • 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.